SPOT-MAS Cancer Blood Test: Detect 75 Cancer Subtypes (2025)

SPOT-MAS™ Cancer Blood Test

Test Name SPOT-MAS™ Cancer Blood Test
Purpose Detects early cancer signals across 10 organ systems and 75 cancer subtypes by analysing circulating tumour DNA (ctDNA) using next-generation sequencing and artificial intelligence.
Recommended For Adults aged 40 and above, or individuals at higher risk of cancer due to factors such as family history, chronic liver disease, smoking, or genetic predisposition.
Price $899 NETT and inclusive of GST
Appointment Options Same-day appointment (subject to availability).
Book via WhatsApp: 8883 8128 or email: hi@atamed.sg
Clinic Locations Orchard: 1 Orchard Blvd #05-09 Camden Medical Centre, S248649
Tanjong Pagar: 72 Anson Rd #01-02 Anson House, S079911

What Is the SPOT-MAS Cancer Blood Test?

Developed by Gene Solutions, the SPOT-MAS Multi-Cancer Early Detection Blood Test is a multi-cancer early detection (MCED) screening that identifies DNA fragments shed by tumour cells, to detect potential signs of cancer from a single blood sample.

By utilising advanced genetic sequencing and artificial intelligence (AI), SPOT-MAS can detect early signs of cancer across 10 organ systems and 75 cancer subtypes, including those that do not have existing routine screening programmes.

In Singapore and across Asia, more than 70% of cancer cases in lower- and middle-income countries are diagnosed at a late stage, when treatment options are limited and survival rates are lower. Detecting cancer early significantly improves the chances of successful treatment and long-term outcomes.

Blood sample labelled SPOT-MAS Cancer Blood Test placed on medical form for early cancer screening.

What Cancers Can SPOT-MAS Detect?

SPOT-MAS is designed to screen for early cancer signals across 10 organ systems, covering 75 cancer subtypes that together account for over than 60% of cancer-related deaths in Southeast Asia. These include cancers of the:

  • Breast
  • Colorectum
  • Endometrium (uterus)*
  • Head and neck*
  • Liver and biliary tract*
  • Lungs
  • Oesophagus*
  • Ovaries*
  • Pancreas*
  • Stomach*

*These cancer types currently do not have routine screening programmes.

Detecting common cancers such as breast and colorectal cancer at an early stage can lead to survival rates of over 90%.

How Does the SPOT-MAS Test Work?

The SPOT-MAS test detects small fragments of cancer-related DNA, known as circulating tumour DNA (ctDNA), that are released into the bloodstream by tumour cells. These ctDNA fragments display unique patterns that distinguish them from the DNA of normal cells.

With a single blood draw, the test analyses several features of ctDNA, including genetic mutations, chemical changes, and fragment size, using next-generation sequencing (NGS) and artificial intelligence (AI) technology. This process enables the system to detect potential signs of cancer and identify the most likely tissue where the tumour may have originated, with greater accuracy.

Close-up of red blood cells and tumour DNA fragments showing SPOT-MAS ctDNA cancer detection.

However, it is important to note that SPOT-MAS is not a diagnostic test. Follow-up imaging or confirmatory investigations are still required to establish a definitive diagnosis.

What Are the Benefits of the SPOT-MAS Test?

The SPOT-MAS Cancer Blood Test offers several important benefits for proactive cancer screening:

1. Detects Cancer Early
Identifies cancer signals before symptoms appear, allowing treatment to begin sooner and improving outcomes
2. Screens for Multiple Cancers Simultaneously
Detects early signals from several cancer types in one test, including those that do not have routine screening programmes.
3. Simple, Convenient and Non-Invasive
Requires only one blood draw, making it quick, and suitable for regular monitoring.
4. High Accuracy
Clinically shown to have 78% sensitivity (ability to detect cancer when present), 99.8% specificity (accuracy in confirming absence of cancer), and 84% accuracy in identifying where the cancer may have started.
5. Complements Existing Screenings
Works alongside mammograms, colonoscopies, and pap smears for broader detection coverage.

Who Should Consider the SPOT-MAS Test?

SPOT-MAS is recommended for adults aged 40 years and above, or for individuals under 40 with higher risk factors for cancer:

Patient consulting doctor about SPOT-MAS Cancer Blood Test during pre-screening discussion.

Your doctor may also recommend the test as part of annual health screening if you have multiple lifestyle or genetic risk factors.

How Is the SPOT-MAS Test Performed?

The SPOT-MAS test is conducted in three simple steps:

  1. Consultation and blood collection – A discussion with our doctor will cover your health concerns and suitability for the test. If suitable, a blood sample will be drawn.
  2. Laboratory analysis – The sample is sent to a licensed genomics laboratory for analysis.
  3. Results and follow-up – Test results are typically available within 12 working days and will be reviewed with you by your doctor.

The entire consultation and blood collection process usually takes about 30 to 60 minutes during non-peak hours, including time spent with our doctor. Please contact us to find the ideal time to schedule your appointment.

Understanding Your SPOT-MAS Test Results

SPOT-MAS results are categorised into two main outcomes:

Result Explanation
Negative result No ctDNA signal detected. This means no tumour-related DNA was found in your sample at the time of testing. However, this does not rule out future cancer risk.

Your doctor may recommend repeating the test annually or performing other follow-up tests for monitoring.
Positive result ctDNA signal detected. This indicates tumour-associated DNA was found, and the result may identify one or two potential tissue origins.

Further diagnostic imaging or referral for targeted tests may be needed to confirm whether cancer is present.

How Much Does the SPOT-MAS Cancer Blood Test Cost?

At ATA Medical, we offer the SPOT-MAS Cancer Blood Test alongside other cancer-related screenings. The prices are as follows:

Test Price*
Consultation From $49.05
Cancer Blood Tests
SPOT-MAS Cancer Blood Test $899
LucenceINSIGHT™ Cancer Blood Test (From 5 to 50 Cancers) From $1,098
Cancer-Related Screenings
Mammogram (Women) $201.65
Ultrasound Breast with Mammogram (Women) $305.20
PAP Smear (Women) From $0 (depending on eligible subsidies)
HPV Test (Women) From $0 (depending on eligible subsidies)
Prostate-Specific Antigen (PSA) Blood Test (Men) $38.15
Ultrasound Prostate (Men) $174.40
Stool Occult Blood Test (Faecal Immunochemical Test) $27.25
Colonoscopy From $2,398
*Prices are NETT and inclusive of GST.

We also offer cancer-related tests as part of our health screening packages to provide a more holistic assessment of your overall health.

How Can I Book an Appointment for the SPOT-MAS Cancer Blood Test?

ATA Medical @ Orchard

Address: 1 Orchard Blvd, #05-09 Camden Medical Centre, Singapore 248649
Nearest MRT: Orchard Boulevard Station (TE13)
Contact Number: 6223 0682
Email: camden@atamed.sg
Opening Hours:
Mon - Fri: 8:30 AM to 12:30 PM, 1:30 PM to 5:30 PM
Sat: 8:30 AM to 12:30 PM
Sun & PH: Closed

ATA Medical @ Tanjong Pagar

Address: 72 Anson Rd, #01-02 Anson House, Singapore 079911
Nearest MRT: Tanjong Pagar Station (EW15)
Contact Number: 6223 0682
Email: hi@atamed.sg
Opening Hours:
Mon - Fri: 8:30 AM to 12:30 PM, 1:30 PM to 5:30 PM
Sat: 8:30 AM to 12:30 PM
Sun & PH: Closed

Navigate to Us

ATA Medical (Anson House)

Nearest MRT: EW15 Tanjong Pagar

ATA Medical (Camden Medical Centre)

Nearest MRT: TE13 Orchard Boulevard

Frequently Asked Questions (FAQ)

The SPOT-MAS Cancer Blood Test has been clinically validated in Asia and shown to have 78% sensitivity (ability to detect cancer when present), 99.8% specificity (accuracy in confirming absence of cancer), and 84% accuracy in identifying where the cancer may have started. These figures indicate that the test is highly reliable in detecting early cancer signals while minimising false positives, but it is not a diagnostic test and should be followed by further medical evaluation when needed.
Circulating tumour DNA (ctDNA) refers to small fragments of genetic material released into the bloodstream by tumour cells. Analysing ctDNA can reveal genetic or chemical changes associated with cancer without the need for an invasive tissue biopsy. While ctDNA testing can help detect early cancer signals, follow-up diagnostic tests are still required to confirm and determine the tumour’s location.
Multi-cancer early detection (MCED) tests such as the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy are widely regarded as useful tools for detecting cancer signals early, particularly for cancers without routine screening programmes. These tests analyse tumour DNA fragments in the blood to provide valuable insights, but they do not replace other diagnostic or imaging tests, such as a biopsy, which is required to confirm a diagnosis.
An early cancer detection test identifies cancer-related signals before symptoms develop, improving the likelihood of timely treatment. The SPOT-MAS Cancer Blood Test is one such test, analysing circulating tumour DNA (ctDNA) to detect potential cancer activity across 10 organ systems and 75 cancer subtypes. As with any screening test, positive results require confirmation through imaging or diagnostic investigations recommended by your doctor.
A full blood count (FBC) cannot directly detect cancer but may show abnormalities such as unusual levels of white blood cells, red blood cells, or platelets that suggest further investigation is needed. These changes can sometimes indicate blood-related cancers such as leukaemia, but imaging or specialised tests are still required to confirm a diagnosis. Your doctor will discuss your results and the appropriate next steps if any abnormalities are found.
Certain blood tests can help detect potential signs of cancer by identifying abnormal substances or DNA fragments linked to tumour activity. Tests such as the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy analyse circulating tumour DNA (ctDNA) in the blood to detect early cancer signals, but they do not provide a definitive diagnosis. If abnormalities are found, further imaging or confirmatory investigations are required to confirm whether cancer is present.
Multi-cancer early detection blood tests such as the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy can detect early cancer signals by analysing circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream. These tests use advanced genetic sequencing to identify molecular patterns that may indicate cancer, but confirmatory imaging or biopsy is still required if cancer signals are detected.
Pre-cancerous changes can sometimes be detected through targeted screening tests such as pap smears for cervical cells or colonoscopy for colon polyps. However, general blood tests, including multi-cancer blood tests like the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy, are designed to detect early cancer signals rather than pre-cancer. It is advisable to consult a doctor to determine the most suitable screening test based on your individual risk factors.
SPOT-MAS differs from traditional cancer marker tests by analysing circulating tumour DNA (ctDNA) in the blood rather than measuring protein markers. While cancer marker tests, such as CEA or CA-125, detect elevated substances that may suggest cancer, SPOT-MAS identifies genetic and molecular patterns from tumour DNA, allowing earlier and broader detection across multiple cancer types. However, both types of tests may require follow-up imaging or diagnostic confirmation if abnormalities are found.
Blood work may show indirect signs that require further investigation, such as unexplained anaemia, elevated tumour markers, or abnormal cell counts. These findings are not specific to cancer and can also occur in many non-cancerous conditions. Specialised tests such as ctDNA analysis in the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy are more specific for detecting early cancer-related signals in the blood.
The first test to check for cancer depends on the suspected cancer type and individual risk factors. Initial assessments may include blood tests or imaging, followed by specific screenings such as mammograms, pap smears, or colonoscopies. Multi-cancer blood tests like the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy can also be used for early detection in individuals without symptoms, but confirmatory diagnostic tests are still needed if abnormalities are detected.
Early-stage cancer can be detected through a combination of screening tests, imaging studies, and specialised blood tests. The SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy identify tumour DNA fragments in the blood before symptoms appear, while traditional methods such as mammograms, colonoscopies, pap smears, and HPV tests detect signs specific to certain cancers. Detecting cancer early increases the likelihood of successful treatment and better long-term outcomes.
To get checked for cancer early, schedule regular health screenings based on your age, sex, and risk factors. These may include mammograms, pap smears, HPV tests, colonoscopies, or multi-cancer blood tests such as the SPOT-MAS Cancer Blood Test and the LucenceINSIGHT Liquid Biopsy. Maintaining healthy habits like avoiding smoking, eating a balanced diet, and attending regular check-ups can also help lower cancer risk. It is advisable to consult your doctor to determine the most suitable screenings for you.